<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04952389</url>
  </required_header>
  <id_info>
    <org_study_id>21-003531</org_study_id>
    <nct_id>NCT04952389</nct_id>
  </id_info>
  <brief_title>Acupuncture Therapy for COVID-Related Olfactory Loss</brief_title>
  <official_title>Acupuncture Therapy for COVID-Related Olfactory Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is looking at the role of acupuncture as a treatment for olfactory dysfunction in&#xD;
      patients who tested positive for COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in UPSIT scores</measure>
    <time_frame>Baseline, post-treatment approximately 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in patient-reported subjective olfactory loss</measure>
    <time_frame>Baseline, post-treatment approximately 12 weeks</time_frame>
    <description>Patient-reported subjective olfactory loss measured by a 10-point visual analog scale with 0 representing no sense of smell and 10 representing normal smell.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sino-Nasal Outcome Test (SNOT-22)</measure>
    <time_frame>Baseline, post-treatment approximately 12 weeks</time_frame>
    <description>Patient-reported subjective olfactory loss measured by SNOT-22 questionnaire, rating symptoms experiences from 0 = no problem, 5 = problem as bad as it can be</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Olfactory Dysfunction</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Acupuncture Therapy Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will undergo ten sessions of acupuncture therapy with a licensed acupuncturist in addition to the standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be treated with two times daily budesonide rinses and olfactory (sense of smell) training. This is considered the current standard of care in the treatment of olfactory dysfunction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Acupuncture Therapy</intervention_name>
    <description>Consists of two treatments per week for five weeks</description>
    <arm_group_label>Acupuncture Therapy Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>Twice daily nasal rinses with steroid medication (budesonide)</description>
    <arm_group_label>Acupuncture Therapy Group</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Olfactory Training</intervention_name>
    <description>involves smelling 4 different essential oils (e.g. rose, lemon, clove, and eucalyptus) twice a day for 20 seconds each (after the nasal rinse)</description>
    <arm_group_label>Acupuncture Therapy Group</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older.&#xD;
&#xD;
          -  Patients with post-viral olfactory dysfunction &gt; 4 weeks.&#xD;
&#xD;
          -  History of positive COVID-19 PCR.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Less than 18 years of age.&#xD;
&#xD;
          -  Active sinus infection.&#xD;
&#xD;
          -  New diagnosis of untreated CRS.&#xD;
&#xD;
          -  Prior diagnosis of dementia or Parkinson's disease.&#xD;
&#xD;
          -  Prior head trauma or neurosurgical procedure resulting in olfactory loss.&#xD;
&#xD;
          -  Patients who do not speak or read English.&#xD;
&#xD;
          -  Patients unable to understand and sign the study consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janalee Stokken, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Tuchscherer</last_name>
      <phone>507-538-6582</phone>
      <email>Tuchscherer.Amy@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 2, 2021</study_first_submitted>
  <study_first_submitted_qc>July 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Janalee K. Stokken</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

